Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Growth in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a significant growth in short interest in November. As of November 15th, there was short interest totalling 100,500 shares, a growth of 1,004.4% from the October 31st total of 9,100 shares. Based on an average daily trading volume, of 320,400 shares, the days-to-cover ratio is presently 0.3 days.

Astellas Pharma Price Performance

Shares of Astellas Pharma stock traded up $0.12 during trading on Friday, reaching $10.29. 181,212 shares of the stock traded hands, compared to its average volume of 199,832. The company has a debt-to-equity ratio of 0.26, a current ratio of 0.90 and a quick ratio of 0.72. The company has a market capitalization of $18.62 billion, a price-to-earnings ratio of 17.15 and a beta of 0.36. Astellas Pharma has a 52-week low of $9.15 and a 52-week high of $13.14. The business has a fifty day simple moving average of $11.30 and a two-hundred day simple moving average of $10.97.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.13 earnings per share (EPS) for the quarter. The business had revenue of $3.11 billion for the quarter. Astellas Pharma had a return on equity of 10.33% and a net margin of 3.26%. Sell-side analysts expect that Astellas Pharma will post 0.61 EPS for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.